[Free Content] Avanir Scores Positive Alzheimer’s Data; NPS Gets Nod From Panel

Avanir announced positive results from its Phase II trial evaluating the safety of AVP-923 in a 10-week study of 220 alzheimer’s patients. Treatment with AVP-923 resulted in a statistically significant reduction in agitation and caregiver burden. Complete data will be presented at the American Neurological Association’s (ANA) 2014 Meeting , October 12-14. The company plans […]

Arrowhead Research (ARWR)– Great Technology, But is the Company Over-Promising on ARC-520?

Two billion people globally have been infected with hepatitis B (HBV), and approximately 350 million are chronic carriers, including approximately 750,000 persons in the US. Among the chronically infected, 15% – 40% will develop cirrhosis and/or hepatocellular carcinoma.  Each year approximately 5000 people in the US and 1 million worldwide die from cirrhosis, liver failure […]

Quick take on Geron’s Imetelstat abstract

Today we finally got a glimpse at the ongoing investigator sponsored study of Geron (GERN) imetelstat in myelofibrosis. We have previously discussed this program here. The abstract can be found here. An oral presentation is scheduled for Monday, December 9th at 4:45 PM. The study was carried out by Dr. Tefferi at the Mayo Clinic. […]

MYGN – To Myriad Investors – Your Risks are MyRisk

Co-Author: Dr. Tro Kalayjian Myriad (NASDAQ:MYGN) is a molecular diagnostics company that focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests in the United States. Their most well-known tests include BRACAnalysis/ BART, which are tests for hereditary breast and ovarian cancer, and COLARIS, another hereditary cancer test for colon […]

SRPT – A Quick Look At The Chart

Sarepta Therapeutics, Inc – Nasdaq(SRPT) Quick update: A big drop in SRPT today leaving the traders with speculation that there could be a leak about the decision to file for accelerated approval(AA) or not yet. For now, let’s take a look at the chart & check the technical standpoint. Daily Chart The price has been trading […]

PPHM – Peregrine’s Bavituximab future looks bleak

We have previously discussed[1][2] the numerous shortcomings of the overhyped oncology developer, Peregrine Pharmaceuticals (NASDAQ: PPHM). With further details on a botched Phase II trial that still leave many questions, investors still have not woken up to the fact that Bavituximab is worthless. In 2013, we expect to see another failed trial in first-line lung […]